POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)

This study has been completed.
Sponsor:
Information provided by:
UCB, Inc.
ClinicalTrials.gov Identifier:
NCT00160537
First received: September 8, 2005
Last updated: December 13, 2013
Last verified: September 2009

September 8, 2005
December 13, 2013
May 2005
July 2005   (final data collection date for primary outcome measure)
Subjects' satisfaction / dissatisfaction after the first week of treatment.
Subjects’ satisfaction / dissatisfaction after the first week of treatment.
Complete list of historical versions of study NCT00160537 on ClinicalTrials.gov Archive Site
allergic rhinitis symptoms scores over the first week of treatment , subject's satisfaction / dissatisfaction of their choice of treatment after the first week of treatment, time to first feeling of (sufficient) symptom improvement during the first we
allergic rhinitis symptoms scores over the first week of treatment , subject’s satisfaction / dissatisfaction of their choice of treatment after the first week of treatment, time to first feeling of (sufficient) symptom improvement during the first we
Not Provided
Not Provided
 
POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)
A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen

Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Seasonal Allergic Rhinitis
Drug: Levocetirizine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
July 2005
July 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical history of SAR known and treated since 2 years.
  • Positive skin prick test (wheal > 3 mm larger than the diluent control) or RAST (≥3.5 IU/ml) to grass pollen (less than 1 year).
  • Minimum mean T5SS of 8 during the baseline period.

Exclusion Criteria:

  • Have an associated asthma requiring a daily treatment other than β2 short acting agonist prn
  • Have atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids and any other disease requiring the administration of oral or topical corticosteroids
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00160537
A00391, EudraCT 2004-002971-18, POPULAR
Not Provided
Not Provided
UCB, Inc.
Not Provided
Study Director: UCB Clinical Trial Call Center UCB, Inc.
UCB, Inc.
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP